Johnson & Johnson Raises Full-Year Guidance Despite $7 Billion Litigation and Acquisition Charges
Johnson & Johnson (JNJ) reported a significant impact on its third-quarter earnings due to approximately $7 billion in charges. These costs stem from two primary sources: a proposed settlement regarding talc-related litigation and expenses associated with the Firefly Bio transaction and a collaboration with Sail Biomedicines. The talc litigation resolution involves an initial $3 billion payment scheduled for 2027, part of a larger $5.5 billion settlement intended to resolve long-standing legal headwinds. Despite these one-time charges causing a sharp decline in GAAP earnings per share, the company's core business remains robust, with quarterly revenues growing nearly 6%. Significantly, J&J has raised its full-year revenue and earnings guidance. This move suggests management maintains confidence in long-term growth drivers and the stability of its healthcare operations, reinforcing its position as a 'Dividend King' with a 64-year history of annual dividend increases.